State of the Science on Brain Insulin Resistance and Cognitive Decline Due to Alzheimer's Disease

Overview

Journal Aging Dis

Specialty Geriatrics

Date 2023 Aug 23

PMID 37611907

Authors

Elizabeth M Rhea

Manon Leclerc

Hussein N Yassine

Ana W Capuano

Han Tong

Vladislav A Petyuk

Shannon L Macauley

Xavier Fioramonti

Owen Carmichael

Frederic Calon

Zoe Arvanitakis

Affiliations

Soon will be listed here.

Abstract

Type 2 diabetes mellitus (T2DM) is common and increasing in prevalence worldwide, with devastating public health consequences. While peripheral insulin resistance is a key feature of most forms of T2DM and has been investigated for over a century, research on brain insulin resistance (BIR) has more recently been developed, including in the context of T2DM and non-diabetes states. Recent data support the presence of BIR in the aging brain, even in non-diabetes states, and found that BIR may be a feature in Alzheimer's disease (AD) and contributes to cognitive impairment. Further, therapies used to treat T2DM are now being investigated in the context of AD treatment and prevention, including insulin. In this review, we offer a definition of BIR, and present evidence for BIR in AD; we discuss the expression, function, and activation of the insulin receptor (INSR) in the brain; how BIR could develop; tools to study BIR; how BIR correlates with current AD hallmarks; and regional/cellular involvement of BIR. We close with a discussion on resilience to both BIR and AD, how current tools can be improved to better understand BIR, and future avenues for research. Overall, this review and position paper highlights BIR as a plausible therapeutic target for the prevention of cognitive decline and dementia due to AD.

Citing Articles

Association of late-life variability in hemoglobin A1C with postmortem neuropathologies.

Biswas R, Capuano A, Mehta R, Bennett D, Arvanitakis Z Alzheimers Dement. 2025; 21(2):e14471.

PMID: 39968681 PMC: 11863718. DOI: 10.1002/alz.14471.

Exploring the interplay of glucose metabolism, insulin resistance, and neurodegenerative pathologies: insights from streptozotocin and hypoglycaemic in vitro models.

Grunblatt E, Yde Ohki C, Schmitt-Bohrer G, Riederer P, Walitza S J Neural Transm (Vienna). 2025; .

PMID: 39932549 DOI: 10.1007/s00702-025-02891-6.

Review of Associations of Diabetes and Insulin Resistance With Brain Health in Three Harmonised Cohort Studies of Ageing and Dementia.

Biswas R, Capuano A, Mehta R, Barnes L, Bennett D, Arvanitakis Z Diabetes Metab Res Rev. 2025; 41(1):e70032.

PMID: 39873127 PMC: 11774135. DOI: 10.1002/dmrr.70032.

Insulin resistance, cognition, and functional brain network topology in older adults with obesity.

McIntyre C, Lyday R, Su Y, Nicklas B, Simpson S, Deep G bioRxiv. 2025; .

PMID: 39829939 PMC: 11741235. DOI: 10.1101/2024.11.26.625552.

Yu X, He H, Wen J, Xu X, Ruan Z, Hu R Open Med (Wars). 2025; 20(1):20241091.

PMID: 39822993 PMC: 11737369. DOI: 10.1515/med-2024-1091.

References

Jauch-Chara K, Friedrich A, Rezmer M, Melchert U, Scholand-Engler H, Hallschmid M . Intranasal insulin suppresses food intake via enhancement of brain energy levels in humans. Diabetes. 2012; 61(9):2261-8. PMC: 3425399. DOI: 10.2337/db12-0025. View

Woodfield A, Porter T, Gilani I, Noordin S, Li Q, Collins S . Insulin resistance, cognition and Alzheimer's disease biomarkers: Evidence that CSF Aβ42 moderates the association between insulin resistance and increased CSF tau levels. Neurobiol Aging. 2022; 114:38-48. DOI: 10.1016/j.neurobiolaging.2022.03.004. View

Freude S, Plum L, Schnitker J, Leeser U, Udelhoven M, Krone W . Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes. 2005; 54(12):3343-8. DOI: 10.2337/diabetes.54.12.3343. View

Lane E, Hohman T, Jefferson A . Insulin-like growth factor binding protein-2 interactions with Alzheimer's disease biomarkers. Brain Imaging Behav. 2016; 11(6):1779-1786. PMC: 5419882. DOI: 10.1007/s11682-016-9636-0. View

Salkovic-Petrisic M, Knezovic A, Hoyer S, Riederer P . What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research. J Neural Transm (Vienna). 2012; 120(1):233-52. DOI: 10.1007/s00702-012-0877-9. View

Banks W, Jaspan J, Huang W, Kastin A . Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin. Peptides. 1997; 18(9):1423-9. DOI: 10.1016/s0196-9781(97)00231-3. View

Vienberg S, Bouman S, Sorensen H, Stidsen C, Kjeldsen T, Glendorf T . Receptor-isoform-selective insulin analogues give tissue-preferential effects. Biochem J. 2011; 440(3):301-8. DOI: 10.1042/BJ20110880. View

Stanley M, Macauley S, Caesar E, Koscal L, Moritz W, Robinson G . The Effects of Peripheral and Central High Insulin on Brain Insulin Signaling and Amyloid-β in Young and Old APP/PS1 Mice. J Neurosci. 2016; 36(46):11704-11715. PMC: 5125227. DOI: 10.1523/JNEUROSCI.2119-16.2016. View

Vanlandewijck M, He L, Mae M, Andrae J, Ando K, Del Gaudio F . A molecular atlas of cell types and zonation in the brain vasculature. Nature. 2018; 554(7693):475-480. DOI: 10.1038/nature25739. View

10.

Moller D, Yokota A, Caro J, Flier J . Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Mol Endocrinol. 1989; 3(8):1263-9. DOI: 10.1210/mend-3-8-1263. View

11.

Craft S, Baker L, Montine T, Minoshima S, Watson G, Claxton A . Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2011; 69(1):29-38. PMC: 3260944. DOI: 10.1001/archneurol.2011.233. View

12.

Dore S, Kar S, Rowe W, Quirion R . Distribution and levels of [125I]IGF-I, [125I]IGF-II and [125I]insulin receptor binding sites in the hippocampus of aged memory-unimpaired and -impaired rats. Neuroscience. 1997; 80(4):1033-40. DOI: 10.1016/s0306-4522(97)00154-1. View

13.

Tham A, Nordberg A, Grissom F, Carlsson-Skwirut C, Viitanen M, Sara V . Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type. J Neural Transm Park Dis Dement Sect. 1993; 5(3):165-76. DOI: 10.1007/BF02257671. View

14.

Milanova I, Korpel N, Correa-da-Silva F, Berends E, Osman S, la Fleur S . Loss of Microglial Insulin Receptor Leads to Sex-Dependent Metabolic Disorders in Obese Mice. Int J Mol Sci. 2022; 23(6). PMC: 8954452. DOI: 10.3390/ijms23062933. View

15.

Weiss M, Lawrence M . A thing of beauty: Structure and function of insulin's "aromatic triplet". Diabetes Obes Metab. 2018; 20 Suppl 2:51-63. PMC: 6159917. DOI: 10.1111/dom.13402. View

16.

Belfiore R, Rodin A, Ferreira E, Velazquez R, Branca C, Caccamo A . Temporal and regional progression of Alzheimer's disease-like pathology in 3xTg-AD mice. Aging Cell. 2018; 18(1):e12873. PMC: 6351836. DOI: 10.1111/acel.12873. View

17.

Kim J, Basak J, Holtzman D . The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009; 63(3):287-303. PMC: 3044446. DOI: 10.1016/j.neuron.2009.06.026. View

18.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

19.

Boucher J, Kleinridders A, Kahn C . Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol. 2014; 6(1). PMC: 3941218. DOI: 10.1101/cshperspect.a009191. View

20.

Knudsen L, Hansen B, Jensen P, Pedersen T, Vestergaard K, Schaffer L . Agonism and antagonism at the insulin receptor. PLoS One. 2013; 7(12):e51972. PMC: 3531387. DOI: 10.1371/journal.pone.0051972. View